HU9400930D0 - Process for producing compositions for preventing allograft rejection - Google Patents

Process for producing compositions for preventing allograft rejection

Info

Publication number
HU9400930D0
HU9400930D0 HU9400930A HU9400930A HU9400930D0 HU 9400930 D0 HU9400930 D0 HU 9400930D0 HU 9400930 A HU9400930 A HU 9400930A HU 9400930 A HU9400930 A HU 9400930A HU 9400930 D0 HU9400930 D0 HU 9400930D0
Authority
HU
Hungary
Prior art keywords
allograft rejection
producing compositions
preventing allograft
preventing
compositions
Prior art date
Application number
HU9400930A
Other languages
English (en)
Other versions
HUT69725A (en
Inventor
Mitsuaki Isobe
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of HU9400930D0 publication Critical patent/HU9400930D0/hu
Publication of HUT69725A publication Critical patent/HUT69725A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU9400930A 1991-10-01 1992-09-29 Process for producing compositions for preventing allograft rejection HUT69725A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76804491A 1991-10-01 1991-10-01

Publications (2)

Publication Number Publication Date
HU9400930D0 true HU9400930D0 (en) 1994-06-28
HUT69725A HUT69725A (en) 1995-09-28

Family

ID=25081356

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9400930A HUT69725A (en) 1991-10-01 1992-09-29 Process for producing compositions for preventing allograft rejection

Country Status (8)

Country Link
EP (1) EP0610298A1 (hu)
JP (1) JPH07502727A (hu)
AU (1) AU667487B2 (hu)
CA (1) CA2120500A1 (hu)
HU (1) HUT69725A (hu)
MX (1) MX9205637A (hu)
WO (1) WO1993006864A1 (hu)
ZA (1) ZA927503B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CA2129637C (en) * 1992-02-12 1999-05-04 Roy R. Lobb Treatment for inflammatory bowel disease
JPH08500826A (ja) * 1992-08-21 1996-01-30 ジェネンテク，インコーポレイテッド Ｌｆａ−１仲介疾患を処置する方法
US5817515A (en) * 1993-12-23 1998-10-06 Icos Corporation Human B2 integrin alpha subunit antibodies
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1419236A4 (en) 2001-07-24 2005-08-03 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
EP1750747A1 (en) 2004-05-07 2007-02-14 Astellas US LLC Soluble lfa-3 polypeptide for treating viral disorders
EP1756163A2 (en) 2004-06-09 2007-02-28 Genentech, Inc. Method of treating granuloma annulare or sarcoid
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
DE68929477T2 (de) * 1988-09-28 2004-06-03 Dana-Farber Cancer Institute, Boston Interzellulare Adhäsions-Moleküle und deren Bindungsliganden
EP0534944B1 (en) * 1988-11-14 1996-09-11 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
DE69000248T2 (de) * 1989-03-09 1993-01-07 Boehringer Ingelheim Pharma Verwendung von interzellularen adhaesions-molekuelen und deren bindungsliganden bei der behandlung von asthma.
ZA903223B (en) * 1989-04-28 1991-02-27 Baylor College Medicine Dissemination of hiv-1 infected cells
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method

Also Published As

Publication number Publication date
AU667487B2 (en) 1996-03-28
JPH07502727A (ja) 1995-03-23
MX9205637A (es) 1993-05-01
AU2782992A (en) 1993-05-03
HUT69725A (en) 1995-09-28
CA2120500A1 (en) 1993-04-15
EP0610298A1 (en) 1994-08-17
WO1993006864A1 (en) 1993-04-15
ZA927503B (en) 1993-05-03

Similar Documents

Publication Publication Date Title
EP0548365A4 (en) Process for producing implant
HUT61600A (en) Process for producing l-triptophane
HUT63199A (en) Process for producing l-treonin
IL99864A0 (en) Compositions for suppressing allograft rejection
GB2260732B (en) Process for manufacturing micromechanical components
HU9400930D0 (en) Process for producing compositions for preventing allograft rejection
EP0509544A3 (en) Process for producing triazine compounds
HUT59819A (en) Process for producing stabilized pharmaceutical compositions
AU2323492A (en) Method for inhibiting allograft rejection
HU9301807D0 (en) Method for producing dinitro-toluols
HUT58785A (en) Process for producing hypoallergene moth-oils
GB9111628D0 (en) Process for manufacture
HUT62472A (en) Process for producing locqlly applicable pharmaceutically compositions
GR1002175B (en) Method for preparing solid compositions
HUT59695A (en) Process for producing hydroxy-ethyl-amine- and norstai
HUT58699A (en) Process for producing 2-chloro-5-methyl-pyridine
HU910745D0 (en) Process for producing 1-treonine
HUT61530A (en) Process for producing 1-hydroxyalkyl-5-nitroimidazoles
HUT60239A (en) Process for producing glian
GB2242063B (en) Method for manufacturing photoconverter
EP0543633A3 (en) Process for producing 4-amino-3-fluorobenzotrifluoride
HUT62849A (en) Process for producing alkenols
GB2267705B (en) Process for producing 2-alkyl-4-halo-5-formylimidazoles
CS411991A3 (en) Process for producing tall oil
HUT66007A (en) Process for producing guanylthiourea

Legal Events

Date Code Title Description
DFA9 Temporary prot. cancelled due to abandonment